journal
MENU ▼
Read by QxMD icon Read
search

Leukemia & Lymphoma

journal
https://www.readbyqxmd.com/read/28812411/earlier-may-be-better-the-role-of-extracorporeal-photopheresis-ecp-as-prevention-of-gvhd-after-allogeneic-transplant
#1
Hannah K Choe, Koen van Besien
No abstract text is available yet for this article.
August 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28805105/economic-burden-of-multiple-myeloma-among-patients-in-successive-lines-of-therapy-in-the-united-states
#2
Joanna P MacEwan, Katharine Batt, Wes Yin, Desi Peneva, Steve Sison, Seanna Vine, Clara Chen
This study characterized the costs of multiple myeloma (MM) during first-line (1L), second-line (2L) and third-line (3L) treatment from the US payer perspective. Patients with ≥2 outpatient or ≥1 inpatient claims with a primary MM diagnosis and 12 months continuous enrollment post index were identified in a retrospective claims database between 1 July 2006 and 30 June 2013. A cost per-patient per-month (PPPM) metric was used to calculate total all-cause and anti-MM pharmacy costs in 1L, 2L, and 3L treatment...
August 13, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28797213/surveillance-imaging-in-mantle-cell-lymphoma-in-first-remission-lacks-clinical-utility
#3
Daniel M Guidot, Jeffrey M Switchenko, Loretta J Nastoupil, Jean L Koff, Kristie A Blum, Joseph Maly, Christopher R Flowers, Jonathon B Cohen
Mantle cell lymphoma (MCL) is a heterogeneous disease with high relapse rates. Limited data guide the use of surveillance imaging following treatment. We constructed a retrospective cohort from two academic institutions of patients with MCL who completed first-line therapy and underwent follow-up for relapse, analyzing the effect of surveillance imaging on survival. Of 217 patients, 102 had documented relapse, with 38 (37%) diagnosed by surveillance imaging and 64 (63%) by other methods. Relapse diagnosis by surveillance imaging had no significant advantage in overall survival from diagnosis date (hazard ratio [HR] = 0...
August 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28797197/dysregulated-expression-of-skp2-and-its-role-in-hematological-malignancies
#4
Michal Kulinski, Iman W Achkar, Mohammad Haris, Said Dermime, Ramzi R Mohammad, Shahab Uddin
S-phase kinase-associated protein 2 (SKP2) is a well-studied F-box protein and a critical part of the Skp1-Cul1-Fbox (SCF) E3 ligase complex. It controls cell cycle by regulating the expression level of p27 and p21 through ubiquitination and proteasomal degradation. SKP2-mediated loss of p27Kip1 is associated with poor clinical outcome in various types of cancers including hematological malignancies. It is however well established that SKP2 is an oncogene, and its targeting may be an attractive therapeutic strategy for the management of hematological malignancies...
August 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28797193/exposure-response-evaluations-of-venetoclax-efficacy-and-safety-in-patients-with-non-hodgkin-lymphoma
#5
Apurvasena Parikh, Sathej Gopalakrishnan, Kevin J Freise, Maria E Verdugo, Rajeev M Menon, Sven Mensing, Ahmed Hamed Salem
Exposure-response analyses were performed for a venetoclax monotherapy study in 106 patients with varying subtypes of non-Hodgkin lymphoma (NHL) (NCT01328626). Logistic regression, time-to-event, and progression-free survival (PFS) analyses were used to evaluate the relationship between venetoclax exposure, NHL subtype and response, PFS, or occurrence of serious adverse events. Trends for small increases in the probability of response with increasing venetoclax exposures were identified, and became more evident when assessed by NHL subtype...
August 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28795871/wendtner-c-m-and-gregor-m-current-perspectives-on-the-role-of-chemotherapy-in-chronic-lymphocytic-leukemia-leuk-lymphoma-2017-http-dx-doi-org-10-1080-10428194-2017-1330474
#6
(no author information available yet)
No abstract text is available yet for this article.
August 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28795850/selection-and-characterization-of-antibody-clones-are-critical-for-accurate-flow-cytometry-based-monitoring-of-cd123-in-acute-myeloid-leukemia
#7
Nicole M Cruz, Mayumi Sugita, Nathan Ewing-Crystal, Linda Lam, Roman Galetto, Agnes Gouble, Julianne Smith, Duane C Hassane, Gail J Roboz, Monica L Guzman
No abstract text is available yet for this article.
August 10, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28792269/early-infectious-complications-among-patients-treated-with-induction-compared-to-hypomethylating-therapy-for-acute-myeloid-leukemia
#8
Marla M Jalbut, Andrew M Brunner, Philip C Amrein, Karen K Ballen, Gabriela S Hobbs, Ashley M Perry, Christelle P Joseph, Amir T Fathi
No abstract text is available yet for this article.
August 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28792268/kit-mutations-correlate-with-adverse-survival-in-children-with-core-binding-factor-acute-myeloid-leukemia
#9
Xi Chen, Hu Dou, Xingjuan Wang, Yi Huang, Ling Lu, Junqing Bin, Yongchun Su, Lin Zou, Jie Yu, Liming Bao
The prevalence and clinical relevance of KIT mutations in childhood core-binding factor (CBF) acute myeloid leukemia (AML) have not been well characterized. In this study, a total of 212 children with de novo AML were enrolled from a Chinese population and 50 (23.5%) of the patients were deemed CBF-AML. KIT mutations were identified in 30% of the CBF-AML cohort. The KIT mutations were clustered in exon 17 and exon 8, and KIT mutations in exons 8 and 17 were correlated with a shorter overall survival (OS) (5-year OS: 30...
August 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28792266/comprehensive-genomic-characterization-dissects-the-complex-biology-of-a-case-of-synchronous-burkitt-lymphoma-and-myeloid-malignancy-with-shared-hematopoietic-ancestry
#10
Georgina L Ryland, Kate Jones, Michelle McBean, Amit Khot, John Francis Seymour, Piers Blombery
No abstract text is available yet for this article.
August 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28792265/sustained-molecular-response-in-chronic-myeloid-leukemia-deep-responders-treated-with-low-dose-tyrosine-kinase-inhibitors
#11
Emilie Cayssials, Florence Tartarin, Joëlle Guilhot, Nathalie Sorel, Jean Claude Chomel, Xavier Leleu, François Guilhot
No abstract text is available yet for this article.
August 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28792264/false-positive-pregnancy-tests-in-females-of-reproductive-potential-receiving-lenalidomide-in-the-united-states
#12
Carmen Castaneda, Neil Minton, Melinda Mezo, Damien Hirsch, Lisa Phillips, Paul Sheehan, Robin McWilliams, May Chan-Liston, Robert Bwire, John Freeman
No abstract text is available yet for this article.
August 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28792260/phase-i-and-randomized-phase-ii-trial-of-panobinostat-in-combination-with-ice-ifosfamide-carboplatin-etoposide-in-relapsed-or-refractory-classical-hodgkin-lymphoma
#13
Bei Hu, Anas Younes, Jason R Westin, Francesco Turturro, Linda Claret, Lei Feng, Nathan Fowler, Sattva Neelapu, Jorge Romaguera, Fredrick B Hagemeister, Maria Alma Rodriguez, Felipe Samaniego, Luis E Fayad, Amanda R Copeland, Loretta J Nastoupil, Yago Nieto, Michelle A Fanale, Yasuhiro Oki
This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE (Schedule A). No DLT was observed at 30 mg. However, frequent (84%) grade-4 thrombocytopenia during second week prompted us to omit the second week of panobinostat 30 mg (Schedule B) for phase II, where this regimen was compared to ICE...
August 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28792255/host-related-immunodeficiency-in-the-development-of-multiple-myeloma
#14
Talib Dosani, Sham Mailankody, Neha Korde, Elisabet Manasanch, Manisha Bhutani, Nishant Tageja, Mark Roschewski, Mary Kwok, Dickran Kazandjian, Rene Costello, Debra Burton, Yong Zhang, David Liewehr, Seth M Steinberg, Irina Maric, Ola Landgren
Host-related immunodeficiency is known to play a role in the development of multiple myeloma (MM) from its precursor conditions (monoclonal gammopathy of undetermined significance, MGUS, smoldering multiple myeloma, SMM). In order to understand the underlying immune changes in this process, we characterized immune patterns from MGUS to SMM to MM. We further sought to identify potential novel immune biomarkers that may predict progression of SMM to MM. We characterized patterns of circulating lymphocytes in 181 patients using multiparametric flow cytometry...
August 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28792253/sorted-peripheral-blood-cells-identify-calr-mutations-in-b-and-t-lymphocytes
#15
Lasse Kjaer, Morten O Holmström, Sabrina Cordua, Mads Hald Andersen, Inge Marie Svane, Mads Thomassen, Torben A Kruse, Niels Pallisgaard, Vibe Skov, Hans C Hasselbalch
No abstract text is available yet for this article.
August 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28786706/low-rap1-interacting-factor-1-and-sirtuin-6-expression-predict-poor-outcome-in-radiotherapy-treated-hodgkin-lymphoma-patients
#16
Hamid Bur, Kirsi-Maria Haapasaari, Taina Turpeenniemi-Hujanen, Outi Kuittinen, Päivi Auvinen, Katja Marin, Ylermi Soini, Peeter Karihtala
Sirtuins (SIRTs) are a family of histone deacetylases, which widely regulate cellular metabolism and are also involved in DNA repair. Rap1-interacting factor 1 (Rif1) and O(6)-alkylguanine DNA alkyltransferase (MGMT) are DNA-repair enzymes, which may potentially be involved in resistance to treatment of classical Hodgkin lymphoma (HL). We assessed the expression levels of (previously unstudied) SIRT1, SIRT4, SIRT6, Rif1, and MGMT immunohistochemically in 85 patients with untreated classical HL. Aberrant distributions of SIRT1, SIRT4, and SIRT6 were detected in Hodgkin neoplastic Reed-Sternberg (RS) cells compared with reactive elements...
August 8, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28782413/coexistence-of-leishmaniasis-and-multiple-myeloma-in-the-era-of-monoclonal-antibody-anti-cd38-or-anti-slamf7-containing-triplets-one-shared-story-of-two-exceptional-cases
#17
Dimitrios C Ziogas, Evangelos Terpos, Maria Gavriatopoulou, Magdalini Migkou, Despoina Fotiou, Maria Roussou, Nikolaos Kanellias, Ioanna Tatouli, Evangelos Eleutherakis-Papaiakovou, Ioannis Panagiotidis, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, Meletios A Dimopoulos
No abstract text is available yet for this article.
August 7, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28782395/myeloablative-busulfan-cytoxan-conditioning-versus-reduced-intensity-fludarabine-melphalan-conditioning-for-allogeneic-hematopoietic-stem-cell-transplant-in-patients-with-acute-myelogenous-leukemia
#18
Vishal Dhere, Scott Edelman, Edmund K Waller, Amelia Langston, Michael Graiser, Erin C Connolly, Jeffrey M Switchenko, Natia Esiashvili, Mohammad K Khan
Fludarabine and melphalan (Flu/Mel) has emerged as a more tolerable chemotherapy-based conditioning regimen compared with busulfan and cyclophosphamide (Bu/Cy) for allogeneic stem cell transplant (allo-hematopoietic stem cell transplantation (HSCT)) patients with acute myelogenous leukemia (AML). We conducted a retrospective review of a single-institution database including patients with AML who received allo-HSCT following conditioning with Mel/Flu or Bu/Cy-based regimens. We performed descriptive statistical analysis to examine patient demographics and clinical outcomes...
August 7, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28776436/chimeric-nup98-nsd1-transcripts-from-the-cryptic-t-5-11-q35-2-p15-4-in-adult-de-novo-acute-myeloid-leukemia
#19
Jarno L Kivioja, Jesus M Lopez Martí, Ashwini Kumar, Mika Kontro, Henrik Edgren, Alun Parsons, Tuija Lundán, Maija Wolf, Kimmo Porkka, Caroline A Heckman
The t(5;11)(q35;p15.4) is a clinically significant marker of poor prognosis in acute myeloid leukemia (AML), which is difficult to detect due to sub-telomeric localization of the breakpoints. To facilitate the detection of this rearrangement, we studied NUP98-NSD1 transcript variants in patients with the t(5;11) using paired-end RNA sequencing and standard molecular biology techniques. We discovered three NUP98-NSD1 transcripts with two fusion junctions (NUP98 exon 11-12/NSD1 exon 6), alternative 5' donor site in NUP98 exon 7, and NSD1 exon 7 skipping...
August 4, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28776428/diagnostic-value-of-serum-ferritin-and-cytokine-profiles-of-hemophagocytic-syndrome-following-allogeneic-hematopoietic-cell-transplantation-methodological-issues
#20
Hideo Koh, Satoru Nanno, Masayuki Hino, Hirohisa Nakamae
No abstract text is available yet for this article.
August 4, 2017: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"